Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
about
Novel therapeutic targets for pancreatic cancerGemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)SIRT1 is involved in oncogenic signaling mediated by GPER in breast cancer.
P2860
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@en
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@nl
type
label
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@en
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@nl
prefLabel
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@en
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@nl
P2093
P2860
P356
P1476
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
@en
P2093
Dao-Jun Gong
Jia-Min Zhang
Qing-Qu Guo
P2860
P304
P356
10.2147/CIA.S45064
P407
P577
2013-07-16T00:00:00Z